PEGylated liposomes: immunological responses
A commonly held view is that nanocarriers conjugated to polyethylene glycol (PEG) are non-immunogenic. However, many studies have reported that unexpected immune responses have occurred against PEG-conjugated nanocarriers. One unanticipated response is the rapid clearance of PEGylated nanocarriers u...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-12-01
|
Series: | Science and Technology of Advanced Materials |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14686996.2019.1627174 |
id |
doaj-28d96beefcd0435db1f50eb1d8a4112f |
---|---|
record_format |
Article |
spelling |
doaj-28d96beefcd0435db1f50eb1d8a4112f2020-11-25T03:24:35ZengTaylor & Francis GroupScience and Technology of Advanced Materials1468-69961878-55142019-12-0120171072410.1080/14686996.2019.16271741627174PEGylated liposomes: immunological responsesMarwa Mohamed0Amr S. Abu Lila1Taro Shimizu2Eman Alaaeldin3Amal Hussein4Hatem A. Sarhan5Janos Szebeni6Tatsuhiro Ishida7Institute of Biomedical Sciences, Tokushima UniversityInstitute of Biomedical Sciences, Tokushima UniversityInstitute of Biomedical Sciences, Tokushima UniversityMinia UniversityMinia UniversityMinia UniversitySemmelweis UniversityInstitute of Biomedical Sciences, Tokushima UniversityA commonly held view is that nanocarriers conjugated to polyethylene glycol (PEG) are non-immunogenic. However, many studies have reported that unexpected immune responses have occurred against PEG-conjugated nanocarriers. One unanticipated response is the rapid clearance of PEGylated nanocarriers upon repeat administration, called the accelerated blood clearance (ABC) phenomenon. ABC involves the production of antibodies toward nanocarrier components, including PEG, which reduces the safety and effectiveness of encapsulated therapeutic agents. Another immune response is the hypersensitivity or infusion reaction referred to as complement (C) activation-related pseudoallergy (CARPA). Such immunogenicity and adverse reactivities of PEGylated nanocarriers may be of potential concern for the clinical use of PEGylated therapeutics. Accordingly, screening of the immunogenicity and CARPA reactogenicity of nanocarrier-based therapeutics should be a prerequisite before they can proceed into clinical studies. This review presents PEGylated liposomes, immunogenicity of PEG, the ABC phenomenon, C activation and lipid-induced CARPA from a toxicological point of view, and also addresses the factors that influence these adverse interactions with the immune system.http://dx.doi.org/10.1080/14686996.2019.1627174accelerated blood clearance (abc) phenomenonanti-peg igmcomplement activationpegylated liposomespolyethylene glycol (peg)complement activation-related pseudoallergy (carpa)hypersensitivity reactions (hsrs) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marwa Mohamed Amr S. Abu Lila Taro Shimizu Eman Alaaeldin Amal Hussein Hatem A. Sarhan Janos Szebeni Tatsuhiro Ishida |
spellingShingle |
Marwa Mohamed Amr S. Abu Lila Taro Shimizu Eman Alaaeldin Amal Hussein Hatem A. Sarhan Janos Szebeni Tatsuhiro Ishida PEGylated liposomes: immunological responses Science and Technology of Advanced Materials accelerated blood clearance (abc) phenomenon anti-peg igm complement activation pegylated liposomes polyethylene glycol (peg) complement activation-related pseudoallergy (carpa) hypersensitivity reactions (hsrs) |
author_facet |
Marwa Mohamed Amr S. Abu Lila Taro Shimizu Eman Alaaeldin Amal Hussein Hatem A. Sarhan Janos Szebeni Tatsuhiro Ishida |
author_sort |
Marwa Mohamed |
title |
PEGylated liposomes: immunological responses |
title_short |
PEGylated liposomes: immunological responses |
title_full |
PEGylated liposomes: immunological responses |
title_fullStr |
PEGylated liposomes: immunological responses |
title_full_unstemmed |
PEGylated liposomes: immunological responses |
title_sort |
pegylated liposomes: immunological responses |
publisher |
Taylor & Francis Group |
series |
Science and Technology of Advanced Materials |
issn |
1468-6996 1878-5514 |
publishDate |
2019-12-01 |
description |
A commonly held view is that nanocarriers conjugated to polyethylene glycol (PEG) are non-immunogenic. However, many studies have reported that unexpected immune responses have occurred against PEG-conjugated nanocarriers. One unanticipated response is the rapid clearance of PEGylated nanocarriers upon repeat administration, called the accelerated blood clearance (ABC) phenomenon. ABC involves the production of antibodies toward nanocarrier components, including PEG, which reduces the safety and effectiveness of encapsulated therapeutic agents. Another immune response is the hypersensitivity or infusion reaction referred to as complement (C) activation-related pseudoallergy (CARPA). Such immunogenicity and adverse reactivities of PEGylated nanocarriers may be of potential concern for the clinical use of PEGylated therapeutics. Accordingly, screening of the immunogenicity and CARPA reactogenicity of nanocarrier-based therapeutics should be a prerequisite before they can proceed into clinical studies. This review presents PEGylated liposomes, immunogenicity of PEG, the ABC phenomenon, C activation and lipid-induced CARPA from a toxicological point of view, and also addresses the factors that influence these adverse interactions with the immune system. |
topic |
accelerated blood clearance (abc) phenomenon anti-peg igm complement activation pegylated liposomes polyethylene glycol (peg) complement activation-related pseudoallergy (carpa) hypersensitivity reactions (hsrs) |
url |
http://dx.doi.org/10.1080/14686996.2019.1627174 |
work_keys_str_mv |
AT marwamohamed pegylatedliposomesimmunologicalresponses AT amrsabulila pegylatedliposomesimmunologicalresponses AT taroshimizu pegylatedliposomesimmunologicalresponses AT emanalaaeldin pegylatedliposomesimmunologicalresponses AT amalhussein pegylatedliposomesimmunologicalresponses AT hatemasarhan pegylatedliposomesimmunologicalresponses AT janosszebeni pegylatedliposomesimmunologicalresponses AT tatsuhiroishida pegylatedliposomesimmunologicalresponses |
_version_ |
1724601432418549760 |